News Daily News Prescribing a Generic for CVD? Plan, Drug Type, and Condition Impact Availability Todd Neale September 13, 2023
News Daily News Borderline Cost-effectiveness for SGLT2 Inhibitors in HFpEF Todd Neale March 15, 2023
News Conference News HRS 2021 Catheter Ablation ‘Good Value’ in CABANA Economic Analysis Michael O'Riordan August 04, 2021
News Daily News Good INR Control on Warfarin Doesn’t Necessarily Predict Future Success, Outcomes Todd Neale September 13, 2018
News Daily News Apixaban Provides ‘Intermediate-Value’ Care, New Economic Analysis Shows Michael O'Riordan March 31, 2017
News Daily News No Money, No Drugs: Global Barriers to Secondary CVD Prevention Caitlin E. Cox October 27, 2015